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Abstract
Female mice were immunized intravaginally with gonococcal outer membrane vesicles (OMV) 
plus microencapsulated IL-12, and challenged using an established model of genital infection with 
Neisseria gonorrhoeae. Whereas sham-immunized and control animals cleared the infection in 10–
13 days, those immunized with OMV plus IL-12 cleared infection with homologous gonococcal 
strains in 6–9 days. Significant protection was also seen after challenge with antigenically distinct 
strains of N. gonorrhoeae, and protective anamnestic immunity persisted for at least 6 months after 
immunization. Serum and vaginal IgG and IgA antibodies were generated against antigens 
expressed by homologous and heterologous strains. Iliac lymph node CD4+ T cells secreted IFNγ, 
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but not IL-4, in response to immunization, and produced IL-17 in response to challenge regardless 
of immunization. Antigens recognized by immunized mouse serum included several shared 
between gonococcal strains, including two identified by immunoproteomics approaches as EF-Tu 
and PotF3. Experiments with immunodeficient mice showed that protective immunity depended 
upon IFNγ and B cells, presumably to generate antibodies. The results demonstrated that 
immunity to gonococcal infection can be induced by immunization with a non-living gonococcal 
antigen, and suggest that efforts to develop a human vaccine should focus on strategies to generate 
Th1-driven immune responses in the genital tract.
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INTRODUCTION
Neisseria gonorrhoeae is a well adapted and exclusively human pathogen that causes the 
sexually transmitted infection, gonorrhea. The most recent estimates based on data collected 
in 2012 indicate an annual incidence of 78 million new cases worldwide 1. The reported 
incidence in the United States is >350,000 cases per year 2, although the real incidence is 
believed to exceed 800,000 cases per year 3. In the absence of a vaccine, control depends 
upon effective screening and diagnosis followed by prompt antibiotic treatment, which are 
not available in all parts of the world. However, N. gonorrhoeae has rapidly developed 
resistance to all classes of antibiotics that have been deployed against it, including most 
recently fluoroquinolones and extended-spectrum cephalosporins, giving rise to fears that 
gonorrhea might become untreatable 4, 5. Infection usually presents as a mucopurulent 
discharge, cervicitis in women and urethritis in men, but >50% of infections in women may 
be clinically inapparent 6. Men typically become aware of infection within a few days, but it 
is increasingly recognized that asymptomatic infection can also occur in men. Women bear 
the greater burden of morbidity, since if left untreated gonorrhea can ascend to the upper 
reproductive tract and cause salpingitis, leading to tubal scarring, infertility, pelvic 
inflammatory disease, and increased risk for ectopic pregnancy which can be life-
threatening. In men untreated infection can progress to prostatitis and epididymitis. 
Newborns delivered through an infected birth canal can acquire eye infections that lead to 
blindness. In both sexes, N. gonorrhoeae can invade systemically, giving rise to disseminated 
gonococcal infection with septic arthritis and dermatitis being the most common 
manifestations. In addition, untreated gonorrhea enhances the transmission and acquisition 
of HIV by up to 5-fold 7.
The emergence of multiple-drug-resistant strains of N. gonorrhoeae has led the WHO and 
the US Centers for Disease Control and Prevention to call for new approaches to treatment 
and renewed efforts at vaccine development 8. Previous attempts to develop a vaccine have 
come to nothing 9. A small-scale trial of a killed whole cell vaccine in Alaska in the 1970s 
was unsuccessful 10. A major effort to develop a vaccine based on gonococcal pilus 
succeeded in inducing protective antibody responses against strains bearing antigenically 
similar pili, but the extensive variability of the pilin protein among naturally occurring N. 
Liu et al. Page 2
Mucosal Immunol. Author manuscript; available in PMC 2017 October 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
gonorrhoeae strains rendered this vaccine totally ineffective in a field trial 11. A more recent 
effort was made to develop a vaccine based on gonococcal porin, the major outer membrane 
protein 12, but plans for a clinical trial were apparently abandoned.
Vaccine efforts are complicated by the extensive antigenic variability of N. gonorrhoeae, in 
which most major surface antigens, including lipooligosaccharide (LOS), porin, pilin, and 
the opacity proteins (Opa) are subject to phase-variable expression (LOS, Opa, pilus), allelic 
variation (porin, Opa), or recombinatorial expression (pilin) (reviewed in 9, 13). In addition, 
it is widely recognized that gonorrhea can be acquired repeatedly with little or no evidence 
of effective immunity being developed as a result of therapeutic recovery from infection. 
Anecdotal evidence going back to the early 20th century indicates that gonorrhea may 
ultimately be self-limiting, suggesting that an infected person might eventually develop a 
sufficient immune response to eliminate the pathogen, but ethical considerations prohibit 
prospective investigation of this. Furthermore, with the possible exception of chimpanzees, 
there are no animal models that closely mimic human infection and disease to permit 
vaccine studies that can be readily translated into clinical trials 14.
However, a small animal model of genital tract gonococcal infection has been established, 
using estradiol-treated female mice 15, 16, and at present this remains the only model in 
which the response of an intact mammalian immune system to genital gonococcal infection 
can be prospectively studied and manipulated. In this model, infection is maintained for 
approximately 10–20 days (depending on various experimental factors) but is eventually 
eliminated probably because N. gonorrhoeae is not adapted to colonize mice. Nevertheless, 
this period of infection provides an opportunity to evaluate host immune responses and to 
test strategies of immunization that inhibit infection and lead to accelerated clearance. 
Notably, infection does not result in specific serum or local genital antibody responses 16, 17. 
Moreover, although some strains of mice (especially BALB/c, but not C57BL/6) develop a 
neutrophil infiltrate into the vagina within a few days, there is no evidence for the induction 
of adaptive type 1 or type 2 T helper (Th1, Th2) cell responses 16–19. In contrast, a Th17 
response occurs with the production of IL-17 and IL-22 19, which upregulate the secretion of 
innate antimicrobial proteins by epithelial cells and the recruitment of neutrophils. 
Abrogation of IL-17-mediated responses with neutralizing antibody or in IL-17 receptor-
knockout mice results in diminished neutrophil influx and prolonged infection, suggesting 
that innate defense mechanisms contribute to clearance 19. Furthermore, if mice are allowed 
to recover from infection and then reinfected, the course of infection is exactly the same as 
in age-matched control mice, and there is no evidence for recall of any anamnestic immune 
response, either elevated antibodies or enhanced Th1, Th2, or Th17 cellular responses 16, 17. 
These findings are reminiscent of the human immune response to uncomplicated gonococcal 
infection, which likewise is minimal with respect to both antibody and T cell-mediated 
responses, regardless of history of prior infection 20, 21. IL-17 is reported to be elevated in 
humans infected with N. gonorrhoeae 22, 23.
Further study of the responses to genital gonococcal infection in mice demonstrated that N. 
gonorrhoeae upregulates the production of the immunosuppressive cytokines, TGFβ and 
IL-10 24, 25. Counteracting these cytokines with neutralizing antibodies allows the 
emergence of Th1-driven responses including anti-gonococcal IgG and IgA antibodies in 
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serum and vaginal secretions, establishment of immune memory, and accelerated clearance 
of inection 24, 25. Subsequent re-infection of such mice without further anti-TGFβ or anti-
IL-10 treatment resulted in resistance to re-infection, and the recall of antibody responses to 
higher levels as well as Th1 (and Th17) cellular responses. These findings imply that N. 
gonorrhoeae suppresses adaptive immune responses, and that reversal of the induced 
immunosuppression enables the development of protective immunity. We have further 
developed this approach to counter-manipulating the ability of N. gonorrhoeae to suppress 
adaptive immune responses that would eliminate it, by treating gonococcus-infected mice 
intravaginally (i.vag.) with IL-12 encapsulated in microspheres (IL-12/ms) 26. This too 
permits the development of protective immunity that not only accelerates clearance of the 
existing infection, but also generates resistance to repeated infection. Because this treatment 
in effect converts the infection into a live vaccine, we hypothesized that microencapsulated 
IL-12 would serve as an adjuvant for a locally administered non-living gonococcal vaccine. 
To test this hypothesis, we have immunized mice i.vag. with a gonococcal outer membrane 
vesicle (OMV) preparation administered with or without IL-12/ms. OMV were selected as a 
vaccine immunogen because they contain most of the surface antigens in native 
conformation, not denatured by heat or chemical inactivation. Moreover, meningococcal 
vaccines have been successfully developed based on OMV preparations from Neisseria 
meningitidis 27. The results demonstrate the generation of a Th1-driven, antibody-
dependent, protective immune response that persists for at least several months and is 
effective against antigenically diverse strains of N. gonorrhoeae.
RESULTS
Intravaginal immunization of mice with gonococcal OMV plus IL-12/ms accelerates 
clearance of challenge infection with N. gonorrhoeae
Groups of 8 female BALB/c mice were immunized i.vag. with gonococcal OMV (strain 
FA1090; 40µg protein) plus IL-12/ms (1µg IL-12), or with OMV plus control (blank) ms; 
two additional control groups were sham-immunized with IL-12/ms or with blank ms alone. 
Immunizations were repeated 1 week and 2 weeks later, and all mice were challenged after a 
further 2 weeks by i.vag. instillation of N. gonorrhoeae FA1090 (5 × 106 CFU). Control 
(sham-immunized) mice, or mice immunized with OMV plus blank ms cleared the infection 
commencing at day 7 post-challenge and were all cleared by day 15; median days of 
clearance were 10–13. There was no significant difference in the clearance rates between 
these three control groups (Fig. 1a). However, mice immunized with OMV plus IL-12/ms 
cleared the infection beginning at day 6 and were all cleared by day 9; median clearance 
=7.5 days compared to 12 days in mice immunized with OMV plus blank ms (P <0.01, 
Kaplan-Meier; Suppl. Table 1 and Fig. 1a). This experiment was repeated twice more with 
similar results (see Suppl. Table 1 and Suppl. Fig. 1). Further examples of replication of this 
finding can be seen in subsequent experiments reported below, e.g., Figs. 1d, 4, 5a and c 
(and Figs. 5b, d, and e for other gonococcal strains), and Figs. 7a, b, f, and g (with C57BL/6 
mice)
Serum and vaginal wash samples collected after clearance (at termination, day 15 post-
inoculation) were assayed for antibodies against intact gonococci (FA1090) by ELISA. This 
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showed that mice immunized with OMV plus IL-12/ms had developed the highest levels of 
vaginal and serum IgG and IgA antibodies, whereas those mice immunized with OMV plus 
blank ms developed much lower levels of these antibodies (Fig. 1b). Mice that were 
unimmunized and sham-infected showed no antibodies detectable above assay background 
at the starting dilutions, and mice immunized with blank ms alone and infected also did not 
develop detectable antibodies (Fig. 1b). Iliac lymph node (ILN) mononuclear cells collected 
at the same time were stained for surface CD4 expression and for intracellular cytokines, 
and analyzed by flow cytometry. This revealed that only mice immunized with OMV plus 
IL-12/ms generated CD4+/IFNγ+ (and CD8+/IFNγ+) T cells, whereas no mice developed 
significant numbers of CD4+/IL-4+ T cells (Fig. 1c; see also Suppl. Fig. 2). However, all 
mice that were infected with N. gonorrhoeae regardless of immunization developed CD4+/
IL-17+ T cells (Fig. 1c and Suppl. Fig. 2), as observed previously 19, 26. These findings are 
all consistent with the results of our previous experiments, in which mice that were first 
infected with N. gonorrhoeae and then treated i.vag. with IL-12/ms cleared the infection 
significantly faster than infected mice that were untreated or treated with blank ms, and that 
IL-12/ms-treated mice developed serum and vaginal IgG and IgA anti-gonococcal 
antibodies, as well as IFNγ-secreting Th1 cells in the draining ILN 26.
Further experiments were performed to determine the minimum number of immunizations 
required to induce immune resistance to infection. A single dose of OMV plus IL-12/ms 
given i.vag. did not consistently generate resistance to challenge, but two doses of OMV 
(40µg protein) plus IL-12/ms (1µg IL-12) given at an interval of 2 weeks were sufficient to 
induce similar resistance to infection; median clearance =8 days (Fig. 1d; Suppl. Table 1). In 
addition, control immunization with OMV prepared from non-typable Haemophilus 
influenzae (NTHI) plus IL-12/ms failed to induce resistance to N. gonorrhoeae; median 
clearance =13 days (Fig. 1d; Suppl. Table 1). This induced antibodies to NTHI but not to N. 
gonorrhoeae (Suppl. Fig. 3a,b) and generated IFNγ-producing CD4+ and CD8+ cells in the 
ILN (Suppl. Fig. 3c).
Intravaginal immunization with gonococcal OMV plus IL-12/ms induces persistent 
gonococcus-specific antibody responses and Th1 cellular responses
To characterize the local and systemic immune responses after immunization with 1, 2, or 3 
doses of gonococcal OMV plus IL-12/ms and before challenge, serum, vaginal washes, and 
ILN were collected from immunized and control mice 2 weeks after the last immunization. 
Serum anti-gonococcal IgM antibodies were at low levels with little difference between 
experimental groups. IgA and IgG antibodies were not detectable above background in 
vaginal wash or serum samples of mice given blank ms alone. Intravaginal immunization 
with 3 doses of gonococcal OMV plus blank ms elevated vaginal and serum anti-gonococcal 
IgA and IgG antibodies but to a lesser degree than immunization with OMV plus IL-12/ms 
(Fig. 2a). In contrast, immunization with one dose of OMV plus IL-12/ms induced low 
levels of anti-gonococcal antibodies in both serum and vaginal wash; a second dose elevated 
antibody production, but no further elevation was seen after 3 doses (Fig. 2a). Antibodies 
appeared to be specific for N. gonorrhoeae, as they were not detected above control levels 
against E. coli or NTHI. Assay of IgG subclass antibodies in both vaginal wash and serum 
showed a predominance of IgG2a, with lesser amounts of IgG1 and IgG2b and low levels of 
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IgG3 (Suppl. Fig. 4). The production of anti-gonococcal IgA and IgG antibodies in vaginal 
wash and serum peaked at 3 months after immunization with 2 doses of OMV plus 
IL-12/ms, and were still detectable at 6 months after immunization (Figs. 2b,c).
Flow cytometric analysis of ILN cells revealed increased numbers of IFNγ+/CD4+ and 
IFNγ+/CD8+ T cells from mice immunized with OMV plus IL-12/ms compared with those 
from control mice (Fig. 3a). As observed with the antibody responses, one immunization 
was sufficient to induce IFNγ production, and it was further elevated by 2 immunizations; 3 
doses did not further increase it. In contrast, immunization with OMV plus IL-12/ms did not 
significantly increase the numbers of IL-4+/CD4+ and IL-17+/CD4+ T cells relative to 
controls (Fig. 3a). To determine whether the induced IFNγ+/CD4+ (and IFNγ+/CD8+) T 
cells were specific for gonococcal antigens, CD4+ cells isolated from ILN were preloaded 
with CFSE, cultured in vitro for 3 days in the presence of antigen-presenting cells with 
gonococcal OMV or without stimulation as controls, and their proliferation was assessed by 
flow cytometry. CD4+ cells from the ILN of immunized mice proliferated significantly 
more, and produced significantly more IFNγ, in response to stimulation in vitro, than the 
cells from control mice (Suppl. Fig. 5a). No production of IL-4 was seen, but IL-17 was 
generated by CD4+ T cells cultured with gonococcal OMV, regardless of immunization, 
similar to what was observed previously with murine cells stimulated with gonococcal 
antigen in vitro 24 (Suppl. Fig. 5a). IFNγ production by ILN CD4+ T cells remained 
elevated, albeit at slowly declining levels, for 4 months after immunization (Fig. 3b).
In addition, vaginas were excised from euthanized mice 3 days after the last immunization 
and RNA was extracted from the whole tissue. RT-PCR analysis showed that, in comparison 
to controls, immunization with gonococcal OMV plus IL-12/ms significantly enhanced the 
expression of mRNA for IFNγ but not for IL-4 or IL-17 (Suppl. Fig. 5b). IFNγ mRNA 
expression in vaginal tissue, and production of IFNγ by ILN CD4+ cells remained elevated 
for up to 2 months following i.vag. immunization with gonococcal OMV plus IL-12/ms 
(Suppl. Fig. 5c). These findings support the cytokine expression results obtained with cells 
from the draining ILN.
Duration of vaccine-induced resistance to infection
To evaluate the duration of immune resistance, groups of 8 mice were immunized with 
gonococcal OMV plus IL-12/ms, and were challenged with the same strain (FA1090) of N. 
gonorrhoeae at 2, 4, or 6 months after immunization. Compared to age-matched controls that 
were either sham-immunized or immunized with OMV plus blank ms, mice immunized with 
OMV plus IL-12/ms were resistant to N. gonorrhoeae infection when challenged at 2 or 4 
months after immunization; median clearance in controls =11–11.5 days vs. 7 days in 
immunized mice (Suppl. Table 1). Similar results were obtained in a replicate experiment 
when mice were challenged 6 months after immunization; median clearance in controls 
=9.5–10 days vs. 6.5 days in mice immunized with OMV plus IL-12/ms (Fig. 4; Suppl. 
Table 1). After termination anti-gonococcal antibodies were detected in serum and vaginal 
washes (Suppl. Figs. 6a,b). IFNγ-(but not IL-4-) secreting CD4+ T cells were present in ILN 
(Suppl. Fig. 6c). Notably, the antibody and IFNγ responses detected after challenge were 
higher than those before challenge (compare with Figs. 2b,c, and 3b) implying recall of 
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memory. As observed previously, IL-17-secreting T cells were always found after challenge 
with N. gonorrhoeae, regardless of immunization (Suppl. Fig. 6c). Longer time periods were 
not evaluated because mice become increasingly resistant to gonococcal infection as they 
age.
Immunization induces resistance to heterologous strains of N. gonorrhoeae
An important consideration for any vaccine is that it should be effective against different 
strains of the pathogen, as well as those antigenically homologous to the immunizing strain. 
N. gonorrhoeae is well known for its antigenic variability involving most of its surface 
antigens through multiple molecular mechanisms. We therefore determined whether i.vag. 
immunization with one strain of gonococcal OMV would be effective against challenge with 
other strains to a similar extent as challenge with the same strain. At first, mice (8 per group) 
were immunized i.vag. with OMV prepared from strain FA1090 plus IL-12/ms or blank ms, 
and were challenged one month later with N. gonorrhoeae strains FA1090 or MS11 (5 × 106 
CFU). Immunization with FA1090 OMV induced resistance to challenge with either FA1090 
or MS11 to similar extents (Fig. 5a; Suppl. Table 2). After challenge and clearance 
antibodies were elevated to similar levels against MS11 and the Th1 responses indicated by 
IFNγ+/CD4+ T cells in ILN were similarly enhanced (Suppl. Fig. 7a,b,c). In a reciprocal 
manner, immunization with MS11 OMV (plus IL-12/ms) induced resistance to challenge 
with strain FA1090 (Fig. 5b; Suppl. Table 2).
Gonococcal strains FA1090 and MS11 both possess porin of the same major type (PorB.1B) 
although of different subtypes 28, 29. Therefore, to determine whether the major porin type is 
integral to immune resistance, further experiments were performed with strain FA19 (PorB.
1A). Immunization with FA1090 OMV (plus IL-12/ms) induced resistance to challenge with 
FA19 (Fig. 5c; Suppl. Table 2). Antibody responses assayed at termination showed cross-
reactivity against FA19, and IFNγ+/CD4+ T cells in ILN were elevated (Suppl. Fig. 7d,e,f). 
Reciprocally, immunization with FA19 OMV induced resistance to challenge with strain 
FA1090 (Fig. 5d; Suppl. Table 2). Other immunization and challenge combinations (i.e., 
MS11 against FA19, and vice versa) likewise showed similar cross-resistance (Suppl. Table 
2).
N. gonorrhoeae strains FA1090, MS11, and FA19 have been widely used in many 
laboratories and extensively subcultured since their original isolation. As a result, it is 
possible that they have acquired mutations and become altered in some of their 
characteristics. Therefore we also challenged immunized mice with novel clinical strains 
that have been minimally passaged in vitro since their isolation 30. Mice immunized with 
FA1090 OMV plus IL-12/ms were also resistant to challenge with clinical isolates GC68 (a 
PorB.1B strain; Fig. 5e; Suppl. Table 2) and GC69 (PorB.1A; Suppl. Table 2).
Antigens targeted by immunization-induced antibodies
When examined by one-dimensional (1D) SDS-PAGE, the protein profiles of FA1090, 
MS11, and FA19 OMV were similar, but with apparent quantitative as well as qualitative 
variations (Fig. 6a). This was expected based on a previous study using comparative high-
throughput proteomic analysis of OMV from these gonococcal strains 31. Western blot 
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analyses of serum from one mouse (#1) immunized with FA1090 OMV plus IL-12/ms 
against FA1090, MS11 or FA19 OMV separated by SDS-PAGE revealed IgG antibodies 
reactive with bands migrating at approximately 35–80kDa, with reactivity against bands 
present in OMV from all three strains strains (Fig. 6b, lanes 2–4). One of these bands at 
approximately 35kDa may correspond to porin, as H5 antibody reacted with a band of 
similar mobility (Fig. 6b, lane 6). Another serum (#2) displayed strong reactivity against 
three bands migrating at approximately 45–65kDa (Fig. 6b, lane 5), possibly similar to 
antigen bands detected by antibodies in mice that had been intranasally immunized with 
OMV 32. In an effort to identify the ~45–65-kDa antigens, we used immunoproteomic 
approaches consisting of two-dimensional (2D) SDS-PAGE separation of OMV and parallel 
2D SDS-PAGE followed by immunoblotting (2D–immunoblot) and mass spectrometry. The 
three 2D protein maps of OMV revealed by Flamingo staining showed numerous protein 
species and significant differences in the OMV proteome between FA1090, MS11, and FA19 
strains (Fig. 6c,d,e). In contrast, the blotted protein maps showed two spots (Spot 1 and Spot 
2) of masses corresponding to 45kDa and 43kDa, and pI 5.2 and 5.5, respectively (FA1090 
OMV; Fig. 6c), or one spot (Spot 1) with an approximate mass 45kDa and pI 5.2 (MS11 and 
FA19 OMV; Fig. 6d,e). Mass spectrometry analysis of the tryptic peptides obtained from 
Spot 1 and Spot 2 (Fig. 6c,d,e) revealed as top hits translation elongation factor-Tu (EF-Tu) 
and a putative periplasmic polyamine-binding protein, PotF3, respectively (Suppl. Table 3). 
EF-Tu appeared as the most confident antigen as it was immunoreactive in all three 2D–
immunoblots and was identified with the highest confidence (score ranging from 485.0 to 
947.1) and coverage (64.2 to 90.6) in all OMV preparations (Suppl. Table 3).
Immune resistance to N. gonorrhoeae depends on IFNγ and antibody
To determine whether the protective effect of immunization with OMV adjuvanted with 
IL-12/ms is dependent on IFNγ or antibody responses, or on immunity governed by CD4+ 
or CD8+ T cells, we performed immunization experiments using mutant C57BL/6 mice 
deficient in IFNγ (IFNγ-ko) B cells (µMT), CD4+ T cells (CD4-ko), or CD8+ T cells (CD8-
ko). Groups of 8 C57BL/6 wild-type (control) and immumnodeficient mice were immunized 
with FA1090 OMV plus IL-12/ms or blank ms, and challenged with N. gonorrhoeae FA1090 
(5 × 106 CFU) one month later. The course of vaginal gonococcal infection was not altered 
in unimmunized immunodeficient mice relative to wild-type controls. All wild-type and 
immunodeficient mice started to reduce the recoverable gonococcal load from day 7–11 and 
had cleared the infection by day12–14 (median 9–13 days), similar to BALB/c mice used in 
experiments described in the previous sections (Figs. 7a, b, f, and g; Suppl. Table 4).
In contrast to wild-type mice, clearance of gonococcal infection was not accelerated in 
IFNγ-ko or µMT mice immunized with OMV plus IL-12/ms compared to immunization 
with OMV plus blank ms (Fig. 7A,B; Suppl. Table 4; Suppl. Fig. 8a,b). Thus deficiency of 
either IFNγ or B cells abrogated the adjuvant effect of IL-12/ms in generating immune 
resistance to genital gonococcal infection. The production of gonococcus-specific vaginal 
and serum IgA and IgG antibodies induced by OMV plus IL-12/ms in wild-type mice was 
abrogated in IFNγ-ko mice (Fig. 7c,d), and as expected there was no generation of IFNγ by 
the ILN cells of immunized IFNγ-ko mice (not shown). Likewise, in µMT mice there was 
no detectable antibody response to immunization (not shown). In contrast, the numbers of 
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IFNγ+/CD4+ T cells in ILNs of µMT mice immunized with gonococcal OMV plus IL-12/ms 
were not affected, and there was no IL-4 response, while IL-17 responses remained 
unaltered (Fig. 5e). These findings indicate that resistance induced by immunization with 
gonococcal OMV plus IL-12/ms depended on both IFNγ and B cells, the latter presumably 
to produce gonococcus-specific antibodies.
The protective effect of immunization with gonococcal OMV plus IL-12/ms was 
incompletely diminished in CD4-ko, and partially diminished also in CD8-ko mice, in 
comparison with wild-type controls (Fig. 7f,g; Suppl. Table 4; Suppl. Fig. 8c,d). These 
findings suggest that the requirement for CD4+ T cells to generate immune resistance could 
be partially compensated by other cells, including CD8+ or NK cells, which can also 
produce IFNγ. However, CD8+ cells appeared to be less critical for protective immunity.
DISCUSSION
We have demonstrated for the first time that a vaccine-induced state of immune resistance to 
genital gonococcal infection can be reliably generated by an intact mammalian immune 
system. This state of immunity appears to depend on antibody production by B cells, and on 
the generation of IFNγ mainly by CD4+ T cells. I.vag. vaccination of mice with gonococcal 
OMV plus IL-12/ms as an adjuvant induced serum and vaginal IgG and IgA antibodies 
against gonococcal antigens, and IFNγ-secreting CD4+ and CD8+ T cells in the draining 
ILN. Both Th1 cellular and antibody responses persisted for several months after 
immunization, and were capable of eliciting resistance to challenge with N. gonorrhoeae for 
at least 6 months, with the recall of immune memory. I.vag. immunization with gonococcal 
OMV alone, either without adjuvant or with control (blank) ms, induced only weak antibody 
responses with no detectable IFNγ production, and no significant resistance to challenge 
infection. Control immunization with OMV prepared from NTHI plus IL-12/ms did not 
generate immune resistance or antibodies cross-reactive with N. gonorrhoeae, although an 
IFNγ response was induced. Thus, while IFNγ appears to be necessary for resistance to N. 
gonorrhoeae, without specific antibodies it is not sufficient.
It should be noted that all mice eventually clear genital gonococcal infection, usually within 
2–3 weeks regardless of immunization or other treatment. We previously reported that 
IL-17-dependent responses contribute to this since infection is prolonged in IL-17RA-
deficient mice 19, and furthermore, i.vag. treatment with microencapsulated IL-17 shortens 
the course of infection, importantly however without enhancing resistance to re-infection 26. 
Nevertheless, the infection is eventually eliminated in untreated or in IL-17RA-deficient 
mice, probably because N. gonorrhoeae, as an exclusively human pathogen, is not adapted to 
survive for longer periods in mice. For example, N. gonorrhoeae cannot utilize murine 
transferrin as a source of iron 33, nor effectively bind murine factor H or C4B-binding 
protein to inhibit complement activation 34, nor exploit murine epithelial cell receptors as 
effectively as it exploits the human equivalents 35, 36. Nevertheless, we have repeatedly 
found that IL-12/ms, given i.vag. either as a therapeutic treatment of an existing infection 26, 
or as an adjuvant with gonococcal OMV vaccine (this study), enhances Th1-driven 
protective immunity revealed by a significantly shortened course of genital gonococcal 
infection. Notably, a similar dose of free, soluble IL-12 is ineffective 26, indicating that 
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sustained release of IL-12 from the slowly hydrolyzing microspheres over several days is 
necessary to induce the protective immune responses. Possibly, however, the microspheres 
also facilitate uptake by the genital tissues, as reported for another microparticulate 
formulation 37.
What is perhaps most remarkable about the findings presented here, given the well-known 
and extensive antigenic variation shown by N. gonorrhoeae, is that resistance extended to 
heterologous strains as well as against the homologous strain from which the OMV vaccine 
was prepared. The full extent of this cross-protection is unknown at present, but our results 
show that immunization with OMV derived from strain FA1090 enhances resistance equally 
well against strains MS11 and FA19, and vice versa, and that resistance extends to clinical 
isolates of N. gonorrhoeae in addition to these “laboratory strains”. Among the major 
gonococcal surface antigens, we know that FA1090, MS11, and FA19 differ in their porin 
(PorB) molecules. FA1090 and MS11 possess different subtypes of PorB.1B, and FA19 has 
PorB.1A 28. Although not as well characterized, the Opa proteins encoded in their genomes 
differ 29, 38, and their LOS are different 39. Opa proteins and LOS glycan chains are also 
phase-variable, resulting in the expression of different antigenic epitopes 40. Recent 
quantitative proteomic studies revealed additional differences and commonalities in the 
composition of the extracellular proteome (cell envelopes and naturally secreted OMV) 
existing between these gonococcal strains 31.
Consistent with cross-protective immunity, ELISA analysis of antibodies induced by 
immunization revealed quantitatively similar levels of antibodies detectable against the 
different strains, with respect to both IgG and IgA in serum and vaginal washes. The 
antibodies appeared to be specific for N. gonorrhoeae as they were not detected against E. 
coli or NTHI, and they were not generated by immunization with OMV prepared from 
NTHI. Western blot analysis of serum IgG antibodies, however, revealed evidence of 
antigens shared between different strains of N. gonorrhoeae. Bands migrating at 45–65kDa 
resembled those observed in an earlier study on intranasal immunization with gonococcal 
OMV, which found modest partial protection against genital gonococcal infection 32. These 
bands migrated at higher molecular mass than major gonococcal outer membrane proteins 
such as porin and Opa which are in the range 30–40kDa. Although in these studies we did 
not observe putative antibodies against gonococcal Rmp (~25kDa), it will be important to 
determine whether anti-Rmp antibodies are induced, because of their counter-protective 
effect in blocking complement activation by antibodies against other antigens 41. Further 
studies on many more samples of serum and vaginal wash from immunized mice need to be 
undertaken to determine the range of gonococcal antigens detected by the induced 
antibodies.
Immunoproteomics technology has provided vaccine candidate antigens for many infectious 
diseases 42, 43, and our initial efforts have identified two novel gonococcal vaccine 
candidates, EF-Tu in FA1090, MS11, and FA19 OMV, and PotF3 also in FA1090. 
Corroborating these findings both proteins were also identified in quantitative proteomic 
profiling of cell envelopes and OMV derived from four common gonococcal isolates 31. EF-
Tu is of particular interest as it has been identified in both spots and in all analyzed OMV. 
EF-Tu is commonly perceived as a cytosolic GTP-binding protein and an essential factor in 
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protein synthesis, however only 20–30% of its total cellular pool is involved in protein 
synthesis at any given time 44. EF-Tu is encoded by at least two genes and has been 
identified previously in gonococcal periplasm as well as on the surface of bacterial cell 
envelopes and OMVs 45–47. In N. gonorrhoeae two separate open reading frames of identical 
sequences encode EF-Tu (NGO1842 and NGO1858; Suppl. Table 3). In support of our 
findings, EF-Tu has been shown to exhibit many functions associated with pathogenesis and 
to elicit antibody responses during infection by several bacteria, and by a meningococcal 
group B OMV vaccine 48–51. The role of PotF3 in gonococcal pathogenesis and immunity is 
unknown at this point; however, PotF2 appears to function as a polyamine-binding protein, 
and spermine inhibits gonococcal biofilm formation 52. Further immunoproteomic analysis 
of additional samples of serum and vaginal wash from immunized mice is likely to reveal 
many more, hitherto unsuspected gonococcal antigens that might contribute to protective 
immunity against N. gonorrhoeae.
Immune resistance induced by i.vag. immunization with gonococcal OMV plus IL-12/ms 
depended on IFNγ, the key cytokine in Th1-driven responses, as IFNγ-deficient mice did 
not generate protective immunity and antibody responses were substantially diminished. 
Likewise, immune resistance was abrogated in µMT mice which lack B cells and hence the 
ability to generate antibodies, although they retained IFNγ production. Consistent with Th1-
driven immunity, serum and vaginal IgG antibodies were mainly of the IgG2a subclass, 
which in mice is particularly effective in mediating complement activation by the classical 
pathway, and in opsonization for phagocytosis by neutrophils and macrophages 53. However, 
it is unclear at this point which mechanisms of anti-gonococcal defense are most important 
for the observed protection in the murine genital tract. Murine vaginal secretions contain 
both IgG, probably derived largely from the circulation, and locally produced secretory 
IgA 54. Both isotypes of anti-gonococcal antibodies were induced in response to i.vag. 
immunization with OMV plus IL-12/ms, but their relative contribution to defense against 
genital gonococcal infection is unknown at this point. The role of IFNγ may have been to 
skew the IgG isotype response towards IgG2a 55, but it is also possible that it enhanced 
phagocytosis by upregulating the expression of high-affinity FcγR-I on neutrophils and 
macrophages, and by activating macrophages. Other mechanisms of IFNγ-driven T cell-
mediated defense cannot be ruled out, although these might be considered less likely against 
a predominantly extracellular bacterial infection. In addition it is possible that IL-12 may 
have had direct effects on B cells, which express the IL-12 receptor 56, and can respond by 
differentiating and generating antibodies 57–60. This may also help to explain why CD4-
deficiency did not totally abrogate the adjuvant effect of IL-12/ms on immunization with 
OMV for inducing protective responses. In addition, other cells including CD8+ T cells as 
well as possibly NK cells, can serve as an alternative source of IFNγ; deficiency of CD8 
was not strongly detrimental to the adjuvant effect of IL-12/ms.
Two major questions are the extent to which these findings relate to immunity to gonorrhea 
in humans, and whether this approach to vaccination can be developed for human use. The 
answers are not straightforward, in part because the absence of a demonstrable state of 
protective immunity to N. gonorrhoeae in humans means that the determinants or even 
correlates of protection are unknown 9. Previous studies in humans with uncomplicated 
genital gonococcal infection have revealed a paucity of antibody responses in serum and 
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genital secretions 20, 21. In addition, cytokine responses were weak, although inflammatory 
cytokines such as IL-1 and IL-6 were elevated in some women who were co-infected with 
Chlamydia trachomatis or Trichomonas vaginalis in addition to N. gonorrhoeae 20. However, 
these studies performed nearly 20 years ago were limited by the technology for measuring 
cytokines available at the time, and by the existing knowledge of cytokines. For example, 
although IL-17 had been discovered in 1995 61, its significance for anti-microbial defense 
did not become widely appreciated until after 2005 when the Th17 subset of lymphocytes 
was defined 62, 63. There is therefore a need to update these studies on human immune 
responses in gonorrhea, using current multiplex technology for detecting multiple cytokines 
in limited amounts of samples, and including more recently discovered cytokines.
While the mouse model does not fully mimic the human infection or the consequent 
disease 64, nevertheless it remains the only currently available model for the prospective 
investigation of immune responses to N. gonorrhoeae. There are certain parallels between 
what is known about the immune response of mice and humans to N. gonorrhoeae. In the 
absence of intervention in either species, the immune response to uncomplicated lower tract 
infection in females is minimal: there is little or no specific antibody response, and no 
evidence for the generation of effective, recallable immune memory involving Th1 or Th2 
cells. However, two reports indicate that humans infected with gonorrhea have elevated 
IL-17 22, 23, as do female mice infected with N. gonorrhoeae 19. Both mice and humans can 
be re-infected with N. gonorrhoeae with apparently no effective protection, whether 
measured in terms of probablity of acquisition, duration or intensity of infection, or disease, 
arising from prior exposure. Therefore, while it would be mistaken to assume that findings 
in the murine model are directly translatable to humans, our findings raise questions and 
specific hypotheses for evaluation in humans.
The prevailing paradigm for lack of effective immunity to gonorrhea holds that the extensive 
antigenic variation shown by N. gonorrhoeae, involving most of its major surface antigens, 
coupled with multiple mechanisms for resisting complement, enable it to evade whatever 
adaptive immune responses the host may develop. Our studies in mice, presaged by 
conclusions derived from the studies of Hedges et al. in humans 20, 21, reveal that, in 
addition, N. gonorrhoeae suppresses adaptive immune responses by inducing high levels of 
regulatory cytokines TGFβ and IL-10, and type 1 regulatory T cells 17, 24, 25. Counter-
manipulating this suppression by means of neutralizing antibodies to TGFβ and IL-10 17, 25, 
or by the local administration of microencapsulated IL-12 26, allows Th1-governed 
responses to emerge, with the development of specific antibodies, establishment of memory, 
and accelerated clearance of infection.
The current study builds on these findings in the context of vaccination, by demonstrating 
that mice can be immunized against N. gonorrhoeae by the i.vag. administration of a non-
living vaccine (OMV) with a Th1-driving adjuvant, IL-12/ms. Whether this approach is 
applicable to humans remains to be determined. Most likely, i.vag. immunization will not be 
acceptable, and is inapplicable for males; therefore another route of immunization will be 
needed. In addition, other Th1-driving adjuvants may be required. However, the findings 
imply that a vaccine against N. gonorrhoeae may indeed be feasible despite earlier setbacks 
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and subsequent pessimism 64, and they serve to indicate the type of immune responses that 
will need to be induced to generate protective immunity.
METHODS
Mice
All mice, including wild-type BALB/c and C57BL/6 mice, B6.129S7-Ifngtm1Ts/J (IFNγ-
deficient), B6.129S2-Ighmtm1Cgn/J (B cell-deficient; also known as µMT), B6.129S2-
Cd4tm1Mak/J (CD4-deficient), and B6.129S2-Cd8atm1Mak/J (CD8-deficient) mice on a 
C57BL/6 background, were purchased from Jackson Laboratories (Bar Harbor, ME). 
BALB/c mice were used for the experiments unless otherwise specified. Mice were 
maintained in a BSL2 facility in the Laboratory Animal Facility at the University at Buffalo, 
which is fully accredited by AAALAC. All animal use protocols were approved by the 
Institutional Animal Care and Use Committee of the University at Buffalo.
Bacteria
N. gonorrhoeae strain FA1090 was provided by Dr Janne Cannon (University of North 
Carolina at Chapel Hill); strain MS11 was provided by Dr Daniel Stein (University of 
Maryland); strain FA19, and clinical isolates were obtained from the collection of clinical 
strains maintained at the University of North Carolina at Chapel Hill. The original clinical 
strains have been stored at –80°C since initial isolation in 1992 and have been minimally 
subcultured 65. For use in the murine infection model, N. gonorrhoeae strains 9087 and 0336 
were transformed with the streptomycin-resistant rpsL gene from strain FA1090 to generate 
strains GC68 and GC69, respectively. E. coli K12 was provided by Dr Terry Connell 
(University at Buffalo). Non-typeable Haemophilus influenzae (NTHI) strain 6P24H1 was 
provided by Dr Timothy Murphy (University at Buffalo). N. gonorrhoeae was cultured on 
GC agar supplemented with hemoglobin and Isovitalex (BD Diagnostic Systems, Franklin 
Lakes, NJ) and the resultant growth was checked for colony morphology consistent with 
Opa protein and pilus expression. NTHI was cultured on GC agar supplemented with 
hemoglobin only. E. coli was cultured on BHI agar. Bacteria were harvested from plates and 
the cell density was determined as detailed previously 24.
IL-12 microspheres
Murine IL-12 (Wyeth, Philadelphia, PA) was encapsulated into poly-lactic acid 
microspheres using the Phase Inversion Nanoencapsulation technology as previously 
described except that bovine serum albumin was replaced by sucrose (0.1 %, w/w) 66. Blank 
microspheres were prepared in the same way but without IL-12.
Gonococcal outer membrane vesicles (OMV)
After 18–22 h culture on supplemented GC agar, N. gonorrhoeae was harvested from plates 
into ice-cold lithium acetate buffer (pH 5.8) and passed through a 25-gauge needle 10–12 
times to sheer the outer membranes from the bacteria. The suspensions were spun in 
microfuge tubes at 13,000 RPM for 1 min. The supernatants were collected and 
ultracentrifuged at 107,000×g for 2 h. The pellet was washed with 50 mM Tris-HCl (pH 8.0) 
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and resuspended in PBS. Protein was assayed with the Micro BCA protein kit (Thermo 
Scientific, Rockford, IL) or RC DC Protein Assay kit (Bio-Rad, Hercules, CA).
Immunization schedule and mouse vaginal infection model
Groups of 8 female mice between 7 and 9 weeks old were immunized i.vag. with 
gonococcal OMV (40µg protein) of various strains as described, plus IL-12/ms (1µg IL-12) 
or blank ms in a total volume of 40µl PBS; control groups were sham-immunized with 
IL-12/ms or with blank ms alone. Mice were immunized 1 to 3 times with a 7–14 day 
interval, as indicated. After a further 2 weeks to 6 months, immunized mice were infected 
with 5 × 106 CFU live N. gonorrhoeae as previously described,15, 26 with the modification 
that 0.5 mg Premarin (Pfizer, Philadelphia, PA) was used as estradiol administered s.c. on 
days –2, 0, and 2. Vaginal swabs collected daily were quantitatively cultured on GC agar 
supplemented with hemoglobin, Isovitalex, and selective antibiotics (vancomycin, 
streptomycin, nisin, colistin, and trimethoprim) to determine the bacterial colonization 
loads.15, 26 The limit of detection was 100 colony-forming units (CFU) recovered per 
mouse. Gonococcal recovery was counted by an individual who was “blinded” to the 
experimental treatments, and all experiments were repeated 2 or 3 times for verification.
Assay of serum and mucosal antibodies
Samples of vaginal wash and serum were collected from the mice at the indicated time 
points.17, 26 Gonococcus-specific IgA, IgG, IgM, and IgG subclass antibodies IgG1, IgG2a, 
IgG2b, and IgG3 in vaginal washes and sera were measured by ELISA on plates coated with 
whole gonococci, using undiluted vaginal wash and 10-fold diluted serum as starting 
dilutions. 17, 26 Total IgA, IgG, and IgM concentrations in secretions were assayed by 
ELISA on plates coated with anti-IgA, -IgG, or -IgM antibodies (Southern Biotech, 
Birmingham, AL). H5 mouse monoclonal antibody (specific for N. gonorrhoeae porin 
serovar PIB3) or affinity-purified mouse IgA, IgG, and IgM (Southern Biotech) were used to 
establish standard curves. Bound antibodies were detected by alkaline phosphatase-
conjugated goat anti-mouse IgA, IgG, IgM, IgG1, IgG2a, IgG2b, or IgG3 antibody 
(Southern Biotech) and p-nitrophenylphosphate substrate (Southern Biotech). Plates were 
read in a VersaMax microplate reader with SoftMax software (Molecular Devices, 
Sunnyvale, CA) or an ELX800 Universal microplate reader with KC Junior software (Bio-
Tek Instruments, Winooski, VT). Antibody data were expressed as relative (fold increase) to 
the antibody levels detected in control samples (from sham-immunized mice) assayed 
simultaneously.
Flow cytometry
Isolated cells were washed with staining buffer twice, then incubated with the indicated 
antibodies for 30 min on ice, washed, and analyzed on a FACSCalibur cytometer. For 
intracellular staining, cells were first fixed with Cytofix/Cytoperm (eBioscience). Antibodies 
to mouse CD4, CD8, IFNγ, IL-4, and IL-17A conjugated with FITC, PE, or 
allophycocyanin were purchased from eBioscience.
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Lymphocyte isolation and culture
Mononuclear cells were isolated from aseptically harvested ILN using Histopaque 1083 
(Sigma-Aldrich, St Louis, MO) density gradient centrifugation and pooled from 2 or 3 mice 
to provide sufficient numbers of cells for culture. CD4+ T cells were purified through 
negative selection using a Dynal CD4 cell isolation kit (Invitrogen, Carlsbad, CA). Cells 
were cultured in 24-well culture plates at a density of 2 × 106 cells/ml in the presence of 
equal numbers of mitomycin C-inactivated spleen cells to serve as APC, either with no 
stimulus or with 2 × 107 N. gonorrhoeae cells.
Proliferation assays
Cells were labeled with carboxymethyl fluorescein succinimide ester (CFSE; Sigma-
Aldrich).67 CFSE-labeled cells were then washed twice in PBS, recounted, and stimulated as 
described above. Cultured cells were harvested and then stained with allophycocyanin-
conjugated anti-mouse CD4 antibody. The data were acquired by gating on the CD4+ cell 
populations in a FACSCalibur cytometer. The attenuation of CFSE fluorescence was used to 
measure cell proliferation.
Cytokine ELISA
IFNγ, IL-4, and IL-17A levels were measured in triplicate using ELISA kits purchased from 
eBioscience.
Real-time RT-PCR
Total cellular RNA of whole vaginas harvested from the mice was isolated with RNeasy 
Mini Kits (Qiagen, Valencia, CA), and was transcribed to cDNA using the iScript cDNA 
synthesis kit (Bio-Rad, Hercules, CA). Real-time RT-PCR was performed on an iCycler iQ 
detection system (Bio-Rad) using Sybergreen (Bio-Rad) for real-time monitoring of the 
PCR. The primers used were as follows: IFNγ, 5’-TAC TGC CAC GGC ACA GTC ATT 
GAA-3’, 5’-GCA GCG ACT CCT TTT CCG CTT CCT-3’; IL-4, 5’-GAA GCC CTA CAG 
ACG AGC TCA-3’, 5’-ACA GGA GAA GGG ACG CCAT-3’; IL-17A, 5’-TCA GGG TCG 
AGA AGA TGC TG-3’, 5’-TTT TCA TTG TGG AGG GCA GA-3’; β-actin, 5’-CCT AAG 
GCC AAC CGT GAA AAG-3’, 5’-GAG GCA TAC AGG GAC AGC ACA-3’. Relative 
quantification of target genes was analyzed based on the threshold cycle (Ct) determined by 
Bio-Rad iQ5 optical system software.
Western Blot
N. gonorrhoeae OMV preparations were boiled for 5 min in sodium dodecyl sulfate (SDS) 
loading buffer containing 2-mercaptoethanol. Protein quantification was done with the RC 
DC Protein Assay kit. Ten micrograms of protein from each sample was separated on 10% 
polyacrylamide SDS electrophoresis gels. Protein bands were transferred onto nitrocellulose 
membranes using the electrophoresis transfer system (Bio-Rad, Hercules, CA, USA). The 
nitrocellulose membranes were blocked with PBS containing 3% skim milk overnight at 4°C 
before incubation for 2 h with serum samples diluted 1:200, or vaginal wash samples diluted 
1:20 in PBS containing 3% skim milk. Specific antibodies bound to N. gonorrhoeae OMV 
preparations were detected with horseradish peroxidase-conjugated goat anti-mouse-IgG 
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(Santa Cruz Biotechnology, Paso Robles, CA) at a dilution of 1:4000. The Pierce detection 
kit was used for chemiluminescent detection and images were collected with a ChemiDoc 
MP imaging system (Bio-Rad).
Immunoproteomics
Protein concentration in OMV was measured using DC Protein Assay Kit (Bio-Rad). 
Samples of OMV [300µg and 50µg of protein, for two dimensional (2D) SDS-PAGE-
MS/MS analysis and immunoblotting, respectively] were precipitated overnight in 90% 
acetone, washed twice with 100% ice-cold acetone and air-dried. Protein pellets were 
reconstituted in 200µL of rehydration buffer (7M urea, 2M thiourea, 2% CHAPS, 2% 
ASB-14, 1% DTT, 2mM TBP, 2% 3–10 IPG buffer, trace of Orange G) and used to 
rehydrate pH 4–7 ReadyStrip IPG strips (Bio-Rad) overnight at 25°C. Isoelectric focusing 
was carried out using the PROTEAN® i12™ IEF System (Bio-Rad) for a total of 26,000Vh 
with the following settings: 50µA current limit, 8000V rapid ramp for 26,000Vh, 750V hold. 
The second dimension (2D) SDS-PAGE was performed using Criterion TGX Any kD gels 
(Bio-Rad). The proteins were stained overnight in Flamingo fluorescent stain (Bio-Rad) and 
the spots were visualized using the ChemiDoc Imaging System (Bio-Rad). For 
immunoblotting, separated proteins were transferred onto PVDF membranes using the 
TurboBlott transfer system (Bio-Rad). The membranes were blocked for 2h in 5% milk in 
PBS Tween, and probed by overnight incubation with sera from immunized mice, followed 
by incubation with anti-mouse HRP-conjugated antibodies (Bio-Rad). Spots were visualized 
using Clarity Western ECL Substrate and ChemiDoc MP Imaging System (Bio-Rad). 
Proteins on membranes were stained with Novex Reversible Membrane Protein Stain 
(InVitrogen) to overlay positions of selected “anchor” spots with the Flamingo-stained 2D 
gels. Matching spots were excised and the proteins were trypsin digested as described 68. 
Samples containing extracted peptides were desalted using ZipTip C18 (Millipore, Billerica, 
MA) and eluted with 70% acetonitrile/0.1% TFA, and dried in a speed vac. Desalted 
peptides were brought up in 2% acetonitrile in 0.1% formic acid (20µL) and analyzed (2µL) 
by LC/ESI MS/MS with a Thermo Scientific Easy-nLC II (Thermo Scientific, Waltham, 
MA) nano HPLC system coupled to a hybrid Orbitrap Elite ETD (Thermo Scientific) mass 
spectrometer using an instrument configuration as described 69. In-line de-salting was 
accomplished using a reversed-phase trap column (100µm × 20mm) packed with Magic 
C18AQ (5-µm 200Å resin; Michrom Bioresources, Auburn, CA) followed by peptide 
separations on a reversed-phase column (75µm × 250mm) packed with Magic C18AQ (5-µm 
100Å resin; Michrom Bioresources) directly mounted on the electrospray ion source. A 30-
minute gradient from 7% to 35% acetonitrile in 0.1% formic acid at a flow rate of 
400nL/min was used for chromatographic separations. The heated capillary temperature was 
set to 300°C and a spray voltage of 2750V was applied to the electrospray tip. The Orbitrap 
Elite instrument was operated in the data-dependent mode, switching automatically between 
MS survey scans in the Orbitrap (AGC target value 1,000,000, resolution 240,000, and 
injection time 250 milliseconds) with MS/MS spectra acquisition in the linear ion trap (AGC 
target value of 10,000, and injection time 100msec). The 20 most intense ions from the 
Fourier-transform (FT) full scan were selected for fragmentation in the linear trap by 
collision-induced dissociation with normalized collision energy of 35%. Selected ions were 
dynamically excluded for 15sec with a list size of 500 and exclusion mass by mass width 
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±0.5. Data analysis was performed using Proteome Discoverer 1.4 (Thermo Scientific). All 
identified peptides were searched against a N. gonorrhoeae database (FA1090, FA19, and 
MS11) combined with cRAP.fasta, a database of common contaminants (http://
www.thegpm.org/crap/); this creates a list of proteins commonly found in proteomics 
experiments that are present by accident or unavoidable contamination. Trypsin was set as 
the enzyme with maximum missed cleavages set to 2. The precursor ion tolerance was set to 
10 ppm and the fragment ion tolerance was set to 0.8 Da. Variable modifications included 
oxidation on methionine (+15.995 Da) and carbamidomethyl on cysteine (+57.021 Da). Data 
were searched using Sequest HT. All search results were run through Percolator for scoring
Statistical analysis
Data are expressed as the mean ± standard error of the mean (SEM). Data on the effect of 
immunization on recovery of N. gonorrhoeae after inoculation were analyzed using two-way 
ANOVA for repeated measures with Fisher’s protected least significant difference post-hoc 
tests. In addition, Kaplan-Meier analysis with log-rank tests was used to compare clearance 
of infection (defined as the first of 3 successive days of zero recovery) between treatment 
groups. For immune response data, unpaired two-tailed t tests were used to compare the 
mean values between two groups, or ANOVA with Bonferroni post-hoc tests was used for 
multiple comparisons. P <0.05 was considered statistically significant. Statistical analyses 
were performed using Microsoft Excel or Prism 5 (GraphPad Software, San Diego, CA).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. 
I.vag immunization with gonococcal OMV plus IL-12/ms induced resistance to genital 
infection with N. gonorrhoeae, and generated an immune response. a: Mice were immunized 
3 times at 7-day intervals with OMV (40µg protein) from strain FA1090 plus control (blank) 
ms or IL-12/ms (1µg IL-12); control mice were sham-immunized with either blank ms, or 
with IL-12/ms alone. Two weeks after the last immunization, all mice were challenged by 
i.vag. inoculation with N. gonorrhoeae strain FA1090 (5 × 106 CFU), and infection was 
monitored by vaginal swabbing and plating. Left panel: recovery (CFU) of N. gonorrhoeae 
(mean ±SEM, N=8 mice), * P <0.01 (ANOVA); right panel: % of animals remaining 
infected at each time point, P <0.01 (Kaplan-Meier analysis, log-rank test, OMV plus 
IL-12/ms vs. OMV plus blank ms). b: Vaginal wash (left) and serum (right) antibodies 
against strain FA1090 in samples collected after termination (day 15), shown as mean 
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±SEM, N=5 samples; # P <0.05, * P <0.01, Student’s t. c: Intracellular cytokine staining in 
CD4+ cells recovered from ILN at termination (day 15), shown as mean ±SEM, N=3 
samples, % of CD4+ staining for each cytokine; * P <0.01 Student’s t. d: Mice were 
immunized twice at a 14-day interval with gonococcal (Ngo) OMV (40µg protein) plus 
blank ms or IL-12/ms (1µg IL-12); control mice were sham-immunized with blank ms alone 
or with NTHI OMV (40µg protein) plus IL-12/ms (1µg IL-12). Two weeks later, all mice 
were challenged with N. gonorrhoeae FA1090 (5 × 106 CFU). Left panel: recovery (CFU) of 
N. gonorrhoeae (mean ±SEM, N=8 mice), * P <0.01 (ANOVA, gonococcal OMV plus 
IL-12/ms vs. gonococcal OMV plus blank ms); right panel: % of animals remaining infected 
at each time point, P <0.0001 (Kaplan-Meier analysis, log-rank test, gonococcal OMV plus 
IL-12/ms vs. gonococcal OMV plus blank ms).
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Fig. 2. 
Antibody responses generated by immunization with gonococcal OMV plus IL-12/ms, prior 
to gonococcal challenge. a: Vaginal wash (left panel) and serum (right panel) antibodies 
assayed by ELISA 2 weeks after the last immunization with 1, 2, or 3 doses of gonococcal 
OMV (40µg protein) plus IL-12/ms (1µg IL-12). Control samples were obtained from mice 
sham-immunized with blank ms (3 doses); additional mice were immunized 3x with 
gonococcal OMV plus blank ms. Data shown as mean ±SEM, N=5 samples, # P <0.05, * P 
<0.01 relative to control samples (ANOVA). Duration of vaginal wash (b) and serum (c) 
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antibodies in mice immunized with 2 doses of FA1090 OMV plus blank ms or IL-12/ms; 
data shown as mean ±SEM, N=5 samples; C, control samples from unimmunized mice.
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Fig. 3. 
a: T cell cytokine responses in ILN cells induced by immunization with gonococcal OMV 
plus IL-12/ms 2 weeks after the last immunization with 1, 2, or 3 immunizations with 
gonococcal OMV (40µg protein) plus IL-12/ms (1µg IL-12). Control ILN were obtained 
from mice sham-immunized with blank ms (3 doses) and additional mice were immunized 
3x with gonococcal OMV plus blank ms. Data shown as mean ±SEM, N=3 samples, % of 
CD4+ or CD8+ cells staining for each cytokine. * P < 0.01 (Student’s t test) comparing 
immunization with IL-12/ms vs. blank ms. b: Duration of IFNγ responses in CD4+ ILN 
cells 1–6 months after two immunizations with gonococcal OMV plus IL-12/ms or with 
OMV plus blank ms. Data shown as mean ±SEM, N=3 samples, % of CD4+ cells staining 
for IFNγ; C, control ILN from unimmunized mice.
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Fig. 4. 
Resistance to gonococcal (FA1090) challenge persisted for at least 6 months after 
immunization with two doses of gonococcal (FA1090) OMV plus IL-12/ms. Left panel: 
recovery (CFU) of N. gonorrhoeae (mean ±SEM, N=8 mice), * P <0.01 (ANOVA, 
gonococcal OMV plus IL-12/ms vs. gonococcal OMV plus blank ms); right panel: % of 
animals remaining infected at each time point, P <0.001 (Kaplan-Meier analysis, log-rank 
test, gonococcal OMV plus IL-12/ms vs. gonococcal OMV plus blank ms).
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Fig. 5. 
Resistance to heterologous gonococcal challenge. a: One month after immunization with 
FA1090 OMV plus IL-12/ms or blank ms, mice were challenged with N. gonorrhoeae strain 
FA1090 (homologous challenge) or strain MS11 (heterologous challenge). Left panel: 
recovery (CFU) of N. gonorrhoeae (mean ±SEM, N=8 mice), * P <0.001 (ANOVA, for 
comparisons shown); right panel: % of animals remaining infected at each time point, P 
<0.02 for FA1090 challenge, IL-12/ms vs. blank ms; P <0.001 for MS11 challenge, 
IL-12/ms vs. blank ms (Kaplan-Meier analysis, log-rank test). b: Mice immunized with 
MS11 OMV were resistant to challenge with N. gonorrhoeae FA1090. Left panel: recovery 
(CFU) of N. gonorrhoeae (mean ±SEM, N=8 mice), P <0.01 (ANOVA); right panel: % of 
animals remaining infected at each time point), P <0.01 (Kaplan-Meier analysis, log-rank 
test). c: Mice immunized with FA1090 OMV were resistant to challenge with N. 
gonorrhoeae FA19. Left panel: recovery (CFU) of N. gonorrhoeae (mean ±SEM, N=8 mice), 
* P <0.01 (ANOVA, for comparisons shown); right panel: % of animals remaining infected 
at each time point, P <0.01, IL-12/ms vs. blank ms for FA1090 challenge; P <0.0001, 
IL-12/ms vs. blank ms for FA19 challenge (Kaplan-Meier analysis, log-rank test), N=8 
mice. d: Mice immunized with FA19 OMV were resistant to challenge with N. gonorrhoeae 
FA1090. Left panel: recovery (CFU) of N. gonorrhoeae (mean ±SEM, N=8 mice), P <0.01 
(ANOVA); right panel: % of animals remaining infected at each time point), P <0.01 
(Kaplan-Meier analysis, log-rank test). e: Mice immunized with FA1090 OMV were 
resistant to challenge with clinical isolate GC68. Left panel: recovery (CFU) of N. 
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gonorrhoeae (mean ±SEM, N=8 mice), P <0.01 (ANOVA); right panel: % of animals 
remaining infected at each time point), P <0.01 (Kaplan-Meier analysis, log-rank test).
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Fig. 6. 
Immunoproteomics of gonococal OMV. a: SDS-PAGE of OMV preparations from N. 
gonorrhoeae strains FA1090, MS11, and FA19, stained with Coomassie blue. b: Western 
blot analysis of mouse sera tested on gonococcal OMV preparations separated by SDS-
PAGE. Lane 1, control serum from a mouse immunized with FA1090 OMV plus blank ms, 
tested against FA1090 OMV; lanes 2–4, serum #1 from a mouse immunized with FA1090 
OMV plus IL-12/ms, tested against OMV from FA1090 (lane 2), MS11 (lane 3), or FA19 
(lane 4); lane 5, serum #2 from a mouse immunized with FA1090 OMV plus IL-12/ms, 
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tested against OMV from FA1090; lane 6, antibody H5 (anti-porin PIB3) tested against 
FA1090 OMV. c–e: proteome maps of gonococcal OMV derived from FA1090 (c), MS11 
(d), and FA19 (e) revealed by 2D electrophoresis and Flamingo fluorescent staining (left 
panels) and their corresponding immunoblots (right panels) obtained by probing with mouse 
serum #2. Immunoreactive spots subjected to MS/MS analysis are labeled as spots 1 and 2 
(arrows). Molecular mass marker (kDa) indicated on the left.
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Fig. 7. 
Resistance to challenge induced by immunization with gonococcal OMV plus IL-12/ms 
depended on IFNγ and B cells. a: Course of infection (FA1090) in IFNγ-ko vs wild-type 
mice immunized with FA1090 OMV; left panel, recovery (CFU) of N. gonorrhoeae (mean 
±SEM, N=8 mice), • P <0.01 (ANOVA); right panel, % of animals remaining infected at 
each time point, P <0.0001 for wild-type mice, IL-12/ms vs. blank ms (Kaplan-Meier 
analysis, log-rank test). b: Course of infection (FA1090) in µMT vs. wild-type mice 
immunized with FA1090 OMV; left panel, recovery (CFU) of N. gonorrhoeae (mean ±SEM, 
N=8 mice), • P <0.01 (ANOVA); right panel, % of animals remaining infected at each time 
point, P <0.0001 for wild-type mice, IL-12/ms vs. blank ms (Kaplan-Meier analysis, log-
rank test). Vaginal wash (c) and serum (d) antibody responses in IFNγ-ko vs wild-type 
(mean ±SEM, N=5 samples) assayed at termination (day 13). IgA and IgG responses in 
vaginal wash and serum were significant (P <0.05, Student’s t, OMV plus blank ms vs. 
OMV plus IL-12/ms) for wild-type mice, but not for IFNγ-ko mice. e: T cell cytokine 
responses in µMT vs. wild-type mice (mean ±SEM, N=3 samples) assayed at termination 
(day 13). IFNγ response to immunization with OMV plus blank ms vs. OMV plus IL-12/ms 
was significant (P <0.01) for both wild-type and µMT mice (ANOVA). f: Course of infection 
(FA1090) in CD4-ko vs wild-type mice immunized with FA1090 OMV; left panel, recovery 
(CFU) of N. gonorrhoeae (mean ±SEM, N=8 mice), # P <0.05, • P <0.01 (ANOVA) for 
comparisons shown; right panel, % of animals remaining infected at each time point, P 
Liu et al. Page 32
Mucosal Immunol. Author manuscript; available in PMC 2017 October 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
<0.001 for wild-type mice IL-12/ms vs. blank ms, P <0.01 for CD4-ko mice IL-12/ms vs. 
blank ms (Kaplan-Meier analysis, log-rank test). g: Course of infection (FA1090) in CD8-ko 
vs wild-type mice immunized with FA1090 OMV; left panel, recovery (CFU) of N. 
gonorrhoeae (mean ±SEM, N=8 mice), # P <0.05, • P <0.01 (ANOVA) for comparisons 
shown; right panel, % of animals remaining infected at each time point, P <0.001 for wild-
type mice IL-12/ms vs. blank ms, P <0.02 for CD8-ko mice IL-12/ms vs. blank ms (Kaplan-
Meier analysis, log-rank test).
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